Bright Minds (DRUG) Biosciences announced positive and significant topline results from its Phase 2 BREAKTHROUGH clinical trial evaluating BMB-101, a selective 5-HT2C biased agonist, in adult patients with drug-resistant Absence Seizures and Developmental and Encephalopathic Epilepsies. The study met its primary efficacy endpoints in both cohorts, demonstrating robust seizure reduction with a favorable safety and tolerability profile. Key results: BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability; REM sleep improvement in patients with Absence Seizures: mean 90% increase in REM sleep with no change in total sleep duration; Company has initiated preparations for global registrational trials in both DEE and Absence Seizure patients
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRUG:
- Bright Minds Biosciences Sets January 6 Webcast for BMB-101 Phase 2 Topline Results in Drug-Resistant Absence Seizures
- 3 ‘Strong Buy’ Stocks to Buy Today, 12/31/2025, According to Top Analysts
- Bright Minds Biosciences: Buy Rating Reiterated on BMB-101’s Potential Best-in-Class Profile and Multi-Billion-Dollar Peak Sales Opportunity
- Is DRUG a Buy, Before Earnings?
- Bright Minds Biosciences Strengthens Advisory Board with PWS Experts